The company posted a triple whiff, coming in under pundit projections for revenue, profitability, and top-line guidance.

AdaptHealth (NASDAQ:AHCO – Free Report) had its target price reduced by Robert W. Baird from $16.00 to $14.00 in a report ...

Adapthealth ( (AHCO) ) has released its Q3 earnings. Here is a breakdown of the information Adapthealth presented to its investors. AdaptHealth ...

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 9.9%. Looking ahead, revenue ...

Baird analyst Eric Coldwell maintained AdaptHealth with an Outperform and lowered the price target from $16 to $14. Canaccord Genuity analyst Richard Close maintained the stock with a Buy and cut the ...

UBS lowered the firm’s price target on AdaptHealth (AHCO) to $12 from $13 and keeps a Buy rating on the shares following the earnings ...

Q3 2024 Earnings Conference Call November 5, 2024 8:30 AM ET. Company Participants. Suzanne Foster - Chief Executive Officer Jason Clemens - Chief ...

AdaptHealth (AHCO) delivered earnings and revenue surprises of 5% and 0.35%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

AdaptHealth published its third-quarter results early that morning, and probably wishes it had taken a sick day for the remainder. Revenue inched up marginally on a year-over-year basis to just ...

AdaptHealth Corp (AHCO) reports steady revenue growth in sleep and respiratory segments, while addressing operational hurdles ...

AdaptHealth reported third quarter net revenue of $805.9 million compared to $804 million, an increase of 0.2% year over year.